Peer-Reviewed Study Placement Bodes Well For Artificial Heart Approval
This article was originally published in The Gray Sheet
SynCardia's artificial heart study is a clinical "triumph" despite its lack of randomization and the relatively few patients who will need the implant, University of Utah cardiologist Dale Runland, MD, opines in a New England Journal of Medicine editorial
You may also be interested in...
A postmarket study of SynCardia's CardioWest Total Artificial Heart (TAH) is needed to confirm that its safety remains in the same range as shown in the firm's non-randomized PMA study, according to FDA's Circulatory System Devices Panel
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.